Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-myeloablative allogeneic stem cell transplant + prophylactic activated donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Abramson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic regimen, developed by the Abramson Cancer Center at Penn Medicine, combines non-myeloablative allogeneic peripheral blood progenitor cell transplantation with a subsequent prophylactic infusion of activated donor lymphocytes (ADLI). The protocol is specifically designed for patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndromes (MDS). The core innovation involves the ex vivo activation of donor T-cells (typically using anti-CD3/anti-CD28 costimulation) prior to infusion. This activation is intended to enhance the graft-versus-leukemia (GVL) effect, improving the donor immune system's ability to identify and eliminate residual malignant cells and combat post-transplant infections, while potentially minimizing the severity of graft-versus-host disease (GVHD) compared to standard donor lymphocyte infusions.
- Other names
- Prophylactic activated DLIDelayed activated donor lymphocyte infusionNon-myeloablative allogeneic peripheral blood progenitor cell transplantation followed by prophylactic activated DLIActivated donor lymphocyte infusion
Beyond the preview
Go deeper on non-myeloablative allogeneic stem cell transplant + prophylactic activated donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-myeloablative allogeneic stem cell transplant + prophylactic activated donor lymphocyte infusion.